MedEx answers any queries you might have regarding Jevtana-60 purchase, shipping and payment terms.
Feel free to contact support through inquiry form, MedeEx is fully dedicated towards your needs 24/7.
Jevtana is an antitumor remedy designed specifically to help people with progressive prostate cancer live longer. The remedy is used with prednisone when prostate cancer progresses and is not amenable to treatment with other remedies, including Docetaxel (Taxotere).
Jevtana helps men fight metastatic prostate cancer with a castration-resistant form of the disease. The remedy can affect not only cancer cells, but also some of the healthy ones. This can cause side effects: low white blood cell count, severe diarrhea, severe allergic reactions and kidney failure. This should be taken into account and discussed with the attending physician.
Jevtana has a unique chemical structure and reduces tumors by attacking rapidly dividing malignant cells so that they can no longer grow and divide. The mechanism of action of the remedy is that it is an inhibitor of microtubules, binds to tubulin, which leads to inhibition of mitotic and interfacial cellular functions.
Jevtana is given in combination with prednisone as an intravenous infusion of 25 mg / m² every 3 weeks; infusion is done within one hour. Prednisone is taken at 10 mg every day throughout the course of prostate cancer treatment.
Modification and reduction of the dose to 20 mg / m² is possible because of side effects: febrile or prolonged (more than one week) neutropenia, diarrhea, peripheral neuropathy of the second degree. If peripheral neuropathy reaches grade 3, cancer treatment should be discontinued despite a reduced dose.
At least 30 minutes prior to the administration of Jevtana dose, to reduce the risk of allergic reactions or to prevent side effects, the patient as a predication regimen is given: antihistamines (Dexchlorpheniramine 5 mg or Diphenhydramine 25 mg or equivalent), corticosteroids (Dexamethasone 8 mg or equivalent steroid), H2 blockers (Ranitidine 50 mg or equivalent).
Researchers abroad are developing a new strategy for delivering chemotherapy to metastatic foci in the bones. Scientists have developed a new system in which nanoparticles with chemotherapy penetrate into bone structures. Bone metastases present a serious problem for patients with prostate cancer, and the use of nanoparticles leads to a significant reduction in tumor size and pain.
Contraindications of the remedy
– the number of neutrophils is less than 1500 / mm3;
– a violation of the liver function (bilirubin ≥1 × CAH or ALT (or) AST ≥1.5 × CAH);
– simultaneous vaccination against yellow fever;
– hypersensitivity to cabazitaxel or other components of the remedy, including polysorbate 80.